• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY: CANF )

1.480 +0.040 (+2.78%)
Official Closing Price Updated: 8:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 213,572
Open 1.420
Bid (Size) 1.420 (1)
Ask (Size) 1.500 (4)
Prev. Close 1.440
Today's Range 1.420 - 1.500
52wk Range 1.290 - 4.690
Shares Outstanding 515,746,293
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
November 22, 2024
Via ACCESSWIRE
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
August 09, 2024
Via ACCESSWIRE

Performance

YTD
-28.50%
-28.50%
1 Month
-24.87%
-24.87%
3 Month
-27.45%
-27.45%
6 Month
-48.43%
-48.43%
1 Year
-29.52%
-29.52%

More News

Read More
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
June 28, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
June 24, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can Fite Biofarma: Q4 Earnings Insights
March 28, 2024
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
June 14, 2024
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via Benzinga
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
June 10, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
June 05, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
May 29, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
May 27, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
May 23, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
May 13, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
May 10, 2024
Via ACCESSWIRE
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
May 09, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
May 06, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 25, 2024
Via Benzinga
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
April 25, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
April 15, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
April 03, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023
March 28, 2024
Via InvestorPlace
Can-Fite Reports 2023 Financial Results and Clinical Update
March 28, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
March 11, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
February 28, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
January 30, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap